Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database
Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/11/1326 |
| _version_ | 1797508316595748864 |
|---|---|
| author | Mansour Tobaiqy Katie MacLure Hajer Elkout Derek Stewart |
| author_facet | Mansour Tobaiqy Katie MacLure Hajer Elkout Derek Stewart |
| author_sort | Mansour Tobaiqy |
| collection | DOAJ |
| description | Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of the attention, the other vaccines should not go unchallenged. This study aimed to determine the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca. A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021. There were 729,496 adverse events for the three vaccines, of which 3420 were thrombotic, mainly Oxford-AstraZeneca (n = 1988; 58.1%) followed by Pfizer (n = 1096; 32.0%) and Moderna (n = 336; 9.8%). As serious adverse events, there were 705 reports of pulmonary embolism for the three vaccines, of which 130 reports (18.4%) were for Moderna, 226 reports (32.1%) for Pfizer and 349 (49.5%) for Oxford-AstraZeneca vaccines. The occurrence of pulmonary embolism is significantly associated with a fatal outcome (<i>p</i> ≤ 0.001). Sixty-three fatalities were recorded (n = 63/3420; 1.8%), of which Moderna (n = 6), Pfizer (n = 25) and Oxford-AstraZeneca (n = 32). |
| first_indexed | 2024-03-10T05:00:22Z |
| format | Article |
| id | doaj.art-9e17540dac0c4dc79f696929a27686f9 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T05:00:22Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-9e17540dac0c4dc79f696929a27686f92023-11-23T01:53:07ZengMDPI AGVaccines2076-393X2021-11-01911132610.3390/vaccines9111326Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance DatabaseMansour Tobaiqy0Katie MacLure1Hajer Elkout2Derek Stewart3Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah P.O. Box 45311, Saudi ArabiaIndependent Researcher, Aberdeen AB32 6RU, UKDepartment of Family and Community Medicine, Medical Faculty, University of Tripoli, Tripoli P.O. Box 13662, LibyaCollege of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, QatarVaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of the attention, the other vaccines should not go unchallenged. This study aimed to determine the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca. A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021. There were 729,496 adverse events for the three vaccines, of which 3420 were thrombotic, mainly Oxford-AstraZeneca (n = 1988; 58.1%) followed by Pfizer (n = 1096; 32.0%) and Moderna (n = 336; 9.8%). As serious adverse events, there were 705 reports of pulmonary embolism for the three vaccines, of which 130 reports (18.4%) were for Moderna, 226 reports (32.1%) for Pfizer and 349 (49.5%) for Oxford-AstraZeneca vaccines. The occurrence of pulmonary embolism is significantly associated with a fatal outcome (<i>p</i> ≤ 0.001). Sixty-three fatalities were recorded (n = 63/3420; 1.8%), of which Moderna (n = 6), Pfizer (n = 25) and Oxford-AstraZeneca (n = 32).https://www.mdpi.com/2076-393X/9/11/1326adverse eventsadverse drug reactionthromboticCOVID-19 vaccinePfizerModerna |
| spellingShingle | Mansour Tobaiqy Katie MacLure Hajer Elkout Derek Stewart Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database Vaccines adverse events adverse drug reaction thrombotic COVID-19 vaccine Pfizer Moderna |
| title | Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database |
| title_full | Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database |
| title_fullStr | Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database |
| title_full_unstemmed | Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database |
| title_short | Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database |
| title_sort | thrombotic adverse events reported for moderna pfizer and oxford astrazeneca covid 19 vaccines comparison of occurrence and clinical outcomes in the eudravigilance database |
| topic | adverse events adverse drug reaction thrombotic COVID-19 vaccine Pfizer Moderna |
| url | https://www.mdpi.com/2076-393X/9/11/1326 |
| work_keys_str_mv | AT mansourtobaiqy thromboticadverseeventsreportedformodernapfizerandoxfordastrazenecacovid19vaccinescomparisonofoccurrenceandclinicaloutcomesintheeudravigilancedatabase AT katiemaclure thromboticadverseeventsreportedformodernapfizerandoxfordastrazenecacovid19vaccinescomparisonofoccurrenceandclinicaloutcomesintheeudravigilancedatabase AT hajerelkout thromboticadverseeventsreportedformodernapfizerandoxfordastrazenecacovid19vaccinescomparisonofoccurrenceandclinicaloutcomesintheeudravigilancedatabase AT derekstewart thromboticadverseeventsreportedformodernapfizerandoxfordastrazenecacovid19vaccinescomparisonofoccurrenceandclinicaloutcomesintheeudravigilancedatabase |